Early clinical stage therapeutics company developing BRY101, a metabolic modulator engineered to increase intracellular NAD, impacting mitochondrial dysfunction, neuroinflammation and oxidative stress.  BRY101 impacts multiple pathways simultaneously, breaking away from the traditional single-target drug development model. This strategy is designed to address the complex mechanisms involved in neurodegenerative and neuromuscular disorders.

Bryleos:  More Life While Living

Bryleos

Wendy Komac

This department provides strategic guidance and insights to the organization from experienced professionals.

Bryleos

Org chart

Teams

Advisory Board

Offices